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Background: Abacavir treatment is associated with drug hypersensitivity reactions in 
~8% of Caucasians, and is highly predicted by the presence of HLA-B*5701 allele. 
Objective: To determine the incidence of ABC-HSR after introduction of prospective 
HLA-B*5701 screening, and to develop new tests to rapidly screen and identify 
susceptible individuals.  
Methods: Prospective study. All individuals prescribed abacavir after January 2002 
were examined (n=138). ABC-HSR was diagnosed utilising standardised criteria. 
HLA results were obtained by sequence-based typing (SBT).   
Diagnostic assay development.  A multiplexed sequence specific primer (SSP) assay 
to identify HLA-B*5701 alleles, and a serological flow cytometry assay for HLA-B57
 
phenotyping using commercial B17 monoclonal
 antibodies and gating on the CD45+ 
lymphocyte population, were developed and validated. 
Results:  Prospective study. Three HLA-B*5701+ individuals developed classical 
ABC-HSR symptoms. In two cases HLA results were not reviewed, while one patient 
with limited treatment options made an informed choice based on the absence of other 
markers of the 57.1 ancestral haplotype. No definite cases of ABC-HSR were 
identified among the 135 HLA-B*5701-negative individuals, with no symptoms in 
96% (n=131). Abacavir was discontinued within 6 weeks due to minor symptoms in 
one case (diarrhoea) or symptoms likely to be associated with an alternative drug in 
three cases (nevirapine = 2, zidovudine =1).  
Diagnostic assay development.  The PCR-SSP assay amplified all HLA-B*5701 
alleles and was able to distinguish between HLA-B*5701 (n=10) and related alleles 
B*5702  (n=2),  B*5703  (n=1),  B*5704 (n=1); and non-HLA-B*57 alleles (n=61). 
Flow cytometry testing of whole blood samples from HLA-B57+ individuals were 
positive (n=7), while all HLA-B57-negative individuals (n=77) tested negative.  
Conclusion: Testing and excluding individuals carrying the susceptibility locus 
HLA-B*5701 has decreased the incidence of abacavir HSR in the WA HIV cohort to 
0% (95% CI 0-0.03) in HLA-B*5701
- individuals. The SSP diagnostic test for HLA-
B*5701 detection is a rapid and accurate typing method with high specificity, 
sensitivity and reproducibility. The B17/CD45 dual staining was sufficient to 
discriminate between individuals carrying B57/B58 antigens and could be used as a 
rapid screen to identify and possibly exclude individuals with potential genetic 
susceptibility to abacavir. Confirmation of the HLA-B57 subtypes must be done 
using molecular methods. 
 
 